Cullinan Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
CGEM
Cullinan Therapeutics, Inc. Common Stock
$16.87 -22.15%
VS MRNAModerna, Inc. Common Stock
$182.11 -0.25%
Cullinan Therapeutics, Inc. Common Stock and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CGEM | MRNA | |
|---|---|---|
| Market Cap | $1.39 billion | $72.70 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | $-204,688,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| CGEM | MRNA | |
|---|---|---|
| Price / Book | 4.33 | 10.75 |
| Price / Sales | — | 32.63 |
CGEM leads on 1 of 1 valuation factors.
Profitability
| CGEM | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | -63.62% | -46.61% |
MRNA leads on 1 of 1 profitability factors.
Risk & Sentiment
| CGEM | MRNA | |
|---|---|---|
| Short Interest | 0.01% | 0.01% |
CGEM leads on 1 of 1 risk & sentiment factors.
Dig deeper: CGEM overview, CGEM financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.